Smith & Nephew SNATS, Inc. (NYSE:SNN) has been given a consensus recommendation of “Hold” by the ten brokerages that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $38.00.

Several research analysts recently issued reports on the company. BidaskClub raised Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research note on Tuesday, August 1st. Zacks Investment Research raised Smith & Nephew SNATS from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a research note on Tuesday, July 11th.

A number of hedge funds have recently bought and sold shares of the company. Dalton Greiner Hartman Maher & Co. raised its stake in Smith & Nephew SNATS by 2,645.8% in the second quarter. Dalton Greiner Hartman Maher & Co. now owns 497,676 shares of the medical equipment provider’s stock worth $17,344,000 after buying an additional 479,551 shares in the last quarter. Citadel Advisors LLC raised its stake in Smith & Nephew SNATS by 456.2% in the first quarter. Citadel Advisors LLC now owns 405,596 shares of the medical equipment provider’s stock worth $12,545,000 after buying an additional 332,669 shares in the last quarter. Karp Capital Management Corp bought a new stake in Smith & Nephew SNATS during the first quarter worth $10,007,000. Cambiar Investors LLC raised its stake in Smith & Nephew SNATS by 6.2% in the first quarter. Cambiar Investors LLC now owns 5,143,756 shares of the medical equipment provider’s stock worth $159,096,000 after buying an additional 301,213 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Smith & Nephew SNATS by 10.9% in the first quarter. Bank of America Corp DE now owns 1,526,036 shares of the medical equipment provider’s stock worth $47,200,000 after buying an additional 149,672 shares in the last quarter. Institutional investors own 7.23% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/08/smith-nephew-snats-inc-snn-given-average-rating-of-hold-by-analysts.html.

Smith & Nephew SNATS (SNN) traded up 0.17% on Tuesday, hitting $35.40. The stock had a trading volume of 121,908 shares. The stock’s 50-day moving average is $34.83 and its 200 day moving average is $32.75. The firm has a market capitalization of $15.50 billion, a price-to-earnings ratio of 18.02 and a beta of 0.76. Smith & Nephew SNATS has a 1-year low of $26.97 and a 1-year high of $35.85.

About Smith & Nephew SNATS

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew SNATS (NYSE:SNN)

Receive News & Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.